David Smadja: Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes
David Smadja, Professor of Hematology (PU-PH) at University of Paris Cité, European Georges Pompidou Hospital, shared on LinkedIn:
”I am pleased to contribute to this international study led by the team of David-Alexandre Trégouët (first author: Gaëlle Munsch), which explores the molecular determinants of the recurrence of venous thromboembolism (VTE).
Through genomic analysis of more than 6,300 patients (including 1,775 recurrences), 28 molecular markers were identified that were associated with the risk of recurrence, revealing that the genetic architecture of this risk varies according to the type of initial event (deep vein thrombosis, pulmonary embolism, induced or not).
These results open up prospects for more personalized medicine, in order to better predict recurrence and adapt the duration of anticoagulant treatments.
This is an important step towards targeted prevention strategies and possible new therapeutic levers.
Reference: Munsch G. et al., Blood 2025 [DOI: 10.1182/blood.2024027879]”
Read the full article here.
Article: Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes
Authors: Gaëlle Munsch, Florian Thibord, Ohanna C. Bezerra, Jennifer A. Brody, Astrid van Hylckama Vlieg, Lenaick Gourhant, Ming-Huei Chen, Floriane Samaria, Marine Germain, Ilana Caro, Pierre Suchon, Robert Olaso, Kerri L. Wiggins, Noémie Saut, Céline Besse, Louisa Goumidi, Delphine Bacq, Laura B. Harrington, Anne Boland, Joseph Emmerich, David M. Smadja, Catherine A. Lemarie, Sven Danckwardt, Stephanie Debette, Jean-François Deleuze, Hélène Jacqmin-Gadda, Marc A. Rodger, France Gagnon, Frits R. Rosendaal, Andrew D. Johnson, Nicholas L. Smith, Francis Couturaud, Pierre-Emmanuel Morange, David-Alexandre Tregouet

Stay informed on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin